Skip to main content

Leslie K. Ferrarelli

Leslie K. Ferrarelli

Science Signaling, AAAS, Washington, DC 20005, USA

Twitter

Latest Stories

Autophagy-independent p62 in metastatic melanoma

By Leslie K. FerrarelliFeb. 5, 2019
SP3 is key to Smac mimetic efficacy

By Leslie K. FerrarelliFeb. 1, 2019
No REST for medulloblastoma

By Leslie K. FerrarelliJan. 25, 2019
Combination therapy is a game of strategy

By Leslie K. FerrarelliJan. 8, 2019
Treating stroke with a microRNA mimic

By Leslie K. FerrarelliDec. 14, 2018
Taking aim at a childhood cancer

By Leslie K. FerrarelliNov. 23, 2018
The two faces of cGAS in cancer and immunity

By Leslie K. FerrarelliNov. 20, 2018
Channeling metastasis pain with VEGF

By Leslie K. FerrarelliOct. 19, 2018
New Connections: VEGF beyond the vasculature

By Leslie K. FerrarelliOct. 16, 2018
Using kinase inhibitors on pseudokinases

By Leslie K. FerrarelliSep. 28, 2018
New connections: Integrated search for therapies

By Leslie K. FerrarelliSep. 25, 2018
A target for medulloblastoma

By Leslie K. FerrarelliSep. 14, 2018
Synthetic lethality with cisplatin

By Leslie K. FerrarelliAug. 21, 2018
Modeling chemotherapy-drug combinations

By Stella Hurtley, Leslie K. FerrarelliJul. 27, 2018
An alternative treatment for leukemia

By Stella Hurtley, Leslie K. FerrarelliJul. 20, 2018
CRISPR, cancer, and p53

By Leslie K. FerrarelliJul. 17, 2018

Latest News

Staff Writers